| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-160287.txt","as_of":"2026-04-18T03:05:05.644967+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-160287.txt","company":"Tango Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-160287.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_b463c8b5841a0c0d","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-160287.txt","content_type":"text/plain","enriched_at":"2026-04-18T03:30:49.237958+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"DEF 14A","final_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-160287.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-160287.txt","source_event_id":"evt_d38408d36aa7","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEF 14A","fp":"b41ccec85e895e23","kind":"sec_filing","published_at":"20260417","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2025-10","2025-06","2025-05","2026-06-04","2026","2026-12-31","2026-04-17","2026-04-18"],"entities":[{"asset_class":"equity","name":"Tango Therapeutics, Inc.","relevance":"high","symbol":"TNGX","type":"issuer"},{"asset_class":"other","name":"PricewaterhouseCoopers LLP","relevance":"medium","symbol":"","type":"auditor"},{"asset_class":"other","name":"vopimetostat","relevance":"medium","symbol":"","type":"drug_candidate"},{"asset_class":"other","name":"TNG456","relevance":"medium","symbol":"","type":"drug_candidate"},{"asset_class":"other","name":"daraxonrasib","relevance":"low","symbol":"","type":"drug_candidate"},{"asset_class":"other","name":"zoldonrasib","relevance":"low","symbol":"","type":"drug_candidate"}],"event_type":"listing","information_gaps":["What changed vs prior known state is not provided in the signal beyond the fact that this DEF 14A was filed.","The specific \u201cAmendment No.\u201d value is blank in the provided text.","The proxy statement\u2019s detailed director nominee names, executive compensation details, and voting procedures are not included in the provided excerpt.","No explicit financial guidance or quantitative financial metrics are disclosed in the provided text (only qualitative program updates and meeting proposals)."],"key_facts":["The document is a definitive proxy statement on Form DEF 14A for Tango Therapeutics, Inc.","The filing indicates the 2026 Annual Meeting of Stockholders will be held virtually on Thursday, June 4, 2026 at 9:00 a.m. Eastern Time.","Stockholders will be asked to: (1) elect three Class II director nominees, (2) ratify PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and (3) approve named executive officers\u2019 compensation on a non-binding advisory basis.","The board recommends voting \u201cFOR\u201d the election of director nominees, \u201cFOR\u201d ratification of PricewaterhouseCoopers LLP, and \u201cFOR\u201d the advisory approval of named executive officers\u2019 compensation.","The filing includes 2025 progress statements for: vopimetostat (positive Phase 1/2 monotherapy data reported in October 2025; plans to initiate a first pivotal study in second line pancreatic cancer in 2026), vopimetostat and Revolution Medicines\u2019 daraxonrasib/zoldonrasib in a Phase 1/2 trial (first patient treated in June 2025; plans to provide a safety and efficacy update in 2026), and TNG456 (first patient treated in May 2025; plans to share initial safety and efficacy data in 2026)."],"numeric_claims":[{"label":"Annual Meeting date","value":"2026-06-04"},{"label":"Annual Meeting time (ET)","value":"9:00 a.m."},{"label":"Number of director nominees","value":"3"},{"label":"Fiscal year ending","value":"2026-12-31"}],"primary_claim":"Tango Therapeutics, Inc. filed a definitive proxy statement on Form DEF 14A for its 2026 Annual Meeting of Stockholders.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Tango Therapeutics, Inc. filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders. The filing outlines proposals for director elections, ratification of the independent auditor, and an advisory vote on executive compensation, and includes updates on several oncology drug programs in 2025.","topics":["SEC filing","DEF 14A","2026 Annual Meeting","director nominees","independent auditor ratification","executive compensation advisory vote","clinical trial updates (2025)","oncology targeted therapies"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEF 14A \u00b7 Tango Therapeutics, Inc. \u00b7 Filed 20260417","ticker":"TNGX","tickers":["TNGX"],"title":"TNGX filed DEF 14A","url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-160287.txt"}... |